Business UpdateJun 18, 2026, 08:06 AM
Scienture Holdings Expands Arbli™ Coverage to 12.5M Lives
AI Summary
Scienture Holdings, Inc. announced significant progress in the commercialization of Arbli™ (losartan potassium oral suspension), including expanded payor coverage for approximately 12.5 million incremental covered lives. The company is also broadening pharmacy access and establishing new channel partnerships to increase patient access across commercial, Medicare, and Medicaid markets. These initiatives aim to strengthen Arbli™'s commercial infrastructure and drive increased prescription volume within the $219 million U.S. losartan market, which sees about 72 million prescriptions annually.
Key Highlights
- Arbli™ secured additional payor coverage for approximately 12.5 million incremental covered lives.
- Arbli™ targets the $219 million U.S. losartan market, with 72 million prescriptions annually.
- Arbli™ is FDA-approved for hypertension in patients over 6 years old, stroke risk reduction, and diabetic nephropathy.
- Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA.
- Arbli™ has a 24-month shelf life from manufacture when stored at room temperature.
- Hypertension affects nearly half of adults in the United States, approximately 119.9 million people.
Price Impact
More from SCNX